Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPLZ7E)

Drug Name

HC-Toxin Drug Info

Synonyms

HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Preclinical	[1]

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID: 107864
ChEBI ID: CHEBI:48028
TTD Drug ID: DMPLZ7E

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Cutaneous T-cell lymphoma	2B01	Approved	[3]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[4]
Panobinostat	DM58WKG	Multiple myeloma	2A83	Approved	[3]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[5]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[6]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[7]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[8]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[9]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell. 1995 Nov;7(11):1941-50.
2	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
3	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
4	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
7	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
8	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
9	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
10	2011 Pipeline of 4SC AG.